University of California San Francisco

Publications

  1. Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events.
    O'Keefe TJ, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace AM, Esserman LJ, Harismendy O, Hirst GL
    NPJ Breast Cancer. 2025 Jul 01; 11(1):63.; 
    PubMed
  2. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H
    Cell Rep Med. 2026 Feb 17; 7(2):102577.; 
    PubMed
  3. Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
    Howard FM, Dolezal J, Hieromnimon H, Venters S, Kochanny S, Li A, Borowsky A, Symmans WF, Wolf D, Brown-Swigart L, Sun A, Basu A, Hirst G, Nguyen LC, Asare A, Kanaparthi S, Khramtsova G, Blenman K, Shan NL, Fan C, Tolaney SM, Somlo G, Hudis CA, Sikov W, McCart L, Watson M, Carey L, Stover DG, Veer LV, Esserman LJ, Perou CM, Pusztai L, Olopade OI, Huo D, Nanda R, Pearson AT
    medRxiv. 2025 Aug 27.; 
    PubMed
  4. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
    Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM
    Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.; 
    PubMed
  5. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele A, Yee D, van 't Veer L, Rugo H, Symmans WF, Goetz MP, Esserman L, Boughey JC
    Breast Cancer Res. 2025 Jun 23; 27(1):115.; 
    PubMed
  6. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
    Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L
    Nat Commun. 2025 Dec 09; 16(1):9945.; 
    PubMed
  7. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, Edwards M, Pass F, Hirst GL, Brown-Swigart L, van 't Veer L, Esserman LJ, Beckwith H, Yee D
    Front Oncol. 2025; 15:1605120.; 
    PubMed
  8. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
    Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R
    Res Sq. 2026 Feb 11.; 
    PubMed
  9. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L
    JCO Precis Oncol. 2025 Jun; 9:e2400776.; 
    PubMed
  10. Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
    Petricoin EF, Wolf DM, Yau C, Wulfkuhle JD, Van't Veer L, Gallagher RI, Esserman LJ, Hirst GL, Brown-Swigart L, Yee D, I-SPY2 Trial Consortium
    Clin Cancer Res. 2025 Oct 15; 31(20):4361-4371.; 
    PubMed